Table 2. Correlations between ZSCAN31 expression and the clinicopathological characteristics of HCC patients.
| Variable | Low ZSCAN31 expression | High ZSCAN31 expression | P value |
|---|---|---|---|
| In general | |||
| Adjacent tissue | 65 | 18 | <0.000# |
| Tumor tissue | 33 | 50 | |
| Sex | |||
| Male | 29 | 41 | 0.55 |
| Female | 4 | 9 | |
| Age (years) | |||
| ≤50 | 9 | 14 | 0.573 |
| >50 | 24 | 36 | |
| Tumor size (cm) | |||
| ≤5 | 18 | 5 | <0.000# |
| >5 | 15 | 45 | |
| HBsAg | |||
| Positive | 30 | 46 | 0.58 |
| Negative | 3 | 4 | |
| Liver cirrhosis | |||
| Yes | 12 | 19 | 0.534 |
| No | 21 | 31 | |
| Portal vein emboli and metastasis | |||
| Yes | 3 | 8 | 0.287 |
| No | 30 | 42 | |
| TNM stage (AJCC) | |||
| 1–2 | 16 | 27 | 0.394 |
| 3–4 | 17 | 23 | |
| Tumor differentiation | |||
| 1–2 | 21 | 31 | 0.534 |
| 3–4 | 12 | 19 | |
#, P values indicate significant difference. Tumor differentiation 1–4 in pathology diagnosis refers to normal tissue, well-differentiated, moderately-differentiated, and poorly differentiated or undifferentiated, respectively. AJCC, American Joint Committee on Cancer.